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Abstract
Background: Surgery and radiation are the mainstays of therapy for human gliomas that are the most common primary
brain tumors. Most recently, cell culture and animal studies provided the first convincing evidence that radiation not only
eliminates tumor cells, but also modulates the immune response and likely improves anti-tumor immunotherapy.
Methology/Pricipal Findings: We present an in vivo study that analyzes the effects of radiation on the immune response in
tumor patients. As readout system, we utilized the reactivity of glioma patients’ sera against antigen GLEA2 as the most
frequent antigen immunogenic in glioblastoma patients. We established an ELISA assay to analyze reactivity of 24
glioblastoma patients over a period of several months. As control we used 30 sera from healthy donors as well as 30 sera
from lung cancer patients. We compared the course of GLEA2 seroreactivity at different times prior, during and after
radiation. The GLEA2 seroreactivity was increased by the time of surgery, decreased after surgery, increased again under
radiation, and slightly decreased after radiation.
Conclusions/Significance: Our results provide in vivo evidence for an increased antibody response against tumor antigens
under radiation. Antigens that become immunogenic with an increased antibody response as result of radiation can serve
as ideal targets for immunotherapy of human tumors.
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Introduction
Malignant gliomas that are derived from the glial lineage
represent a major class of tumors of the central nervous system
(CNS) with glioblastoma multiforme (GBM) as the most common
malignancy of the CNS [1]. Treatment is almost never curative
even for patients with low-grade gliomas. Two-year survival for
patients with glioblastoma is less than 30% [1]. The rate of overall
survival and disease-free survival did not change appreciably over
three decades.
Surgery, radiation and recently temozolomide chemotherapy
have been the basis of therapy [2–4]. Other approaches such as
immunotherapy have yet to find their way into clinical praxis.
Known consequences of ionizing radiation include induction of
double strand DNA breaks, DNA and protein modification by
radical formation [5,6]. Now, it has been shown that radiation can
also modulate the peptide repertoire and enhance the MHC class I
expression [7]. These recent data indicate possibilities that
radiation cannot only be used to eliminate tumor cells, but also
to modify the immune response. As a result of radiation, the tumor
cells may increasingly present specific antigens. These antigens can
subsequently be targeted by immunotherapy.
There are only few immunogenic antigens that have been
reported for gliomas [8–12]. For our study we analysed glioma-
expressed antigen 2 (GLEA2) that shows the most frequent
antibody response in glioma patients [13]. We compared GLEA2
seroreactivity by ELISA prior and after radiotherapy of glioblas-
toma patients.
Materials and Methods
Patients
Patients eligible for this study were 18 to 75 years of age, with a
histological proven glioblastoma multiforme and a Karnofsky
Performance Score of 70 or better. Patients with renal, hepatic or
bone marrow impairment, HIV infection, prior chemotherapy or
stereotactic biopsy were excluded.
In total, 24 cases of newly diagnosed glioblastomas operated
during the period of March 2004 through April 2005 were studied.
All patients (14 males and 10 females) underwent radical tumor
resection. The median patient age was 56.8 years with a range
from 36.9 to 72.5 years. In all cases surgery was followed by
radiotherapy that consisted of fractionated focal irradiation at a
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week over a period of 6 weeks, for a total dose of 60 Gy.
Radiotherapy was delivered to the gross tumor volume with a
2 cm margin volume for the clinical target volume based on a
preoperative magnetic resonance image (MRI). In 17 cases
patients additionally underwent chemotherapy treatment consist-
ing of temozolomide (marketed as TemodalH in Europe and
Canada and TemodarH in the United States; Schering-Plough). In
nine cases chemotherapy was applied concomitant to radiotherapy
at a dose of 75 mg/m
2/d, given 7 days per week from the first day
of radiotherapy until the last day of radiotherapy, but for no longer
than 49 days. After a 4-week break, patients received up to six
cycles of adjuvant temozolomide every 28 days according to the
standard 5-day schedule [4]. In the remaining cases the
radiotherapy regime was followed by an adjuvant chemotherapy
that was administered at a dose of 150 mg/m
2/d on day 1–5 in
the first cycle. The following cycles were done at a dosage of
200 mg/m
2/day. Treatment cycles were repeated every 28 days.
The baseline examination included computer tomography (CT)
or magnetic resonance imaging (MRI), full blood counts and blood
chemistry tests, and a physical examination. All patients were to be
seen every 4 weeks and blood samples were collected. Due to
neurological deficits, some of the patients were not examined in
our outpatient department, but in their own home.
We obtained ethical approval from local ethics committee for
‘‘Development of minimal invasive glioma diagnostics’’ (ethical
approval No. 67106) involving both, Department of Human
Genetics, Saarland University and Neurosurgical Clinic, Saarland
University Medical School. All patients gave written informed
consent for the use of their blood samples for analysis.
Plasmids and cell lines
For baculovirus expression system, we used pBlueBacHis 2a
(Invitrogen, Rockville, MD) to express 6xHis-tagged GLEA2 N-
terminus. Spodoptera frugiperda cell line Sf158 was cultured in
TC100 medium (Invitrogen) supplemented with 10% FBS and 1%
penicillin-streptomycin (Invitrogen) at 27uC in non-humidified
environment.
Protein expression and purification
Infected SF158 cells were incubated for 46 h at 27uC, detached
with a cell scraper and centrifuged for 15 min at 3.000 rpm. The
cell pellet was resuspended in lysis buffer (50 mM NaH2PO4
(pH 8.0), 300 mM NaCl, 5 mM imidazole, 1% NP40, protease
inhibitor cocktail (Roche, Mannheim, Germany)) and incubated
on ice for 20 min. The lysate was centrifuged for 30 min at
40.000 rpm at 4uC. The supernatant was incubated with Ni-NTA
agarose (Qiagen, Hilden, Germany) for 2 h at 4uC on an end-
over-end shaker. Agarose beads were transferred to micro-spin
chromatography columns (Bio-Rad, Hercules, CA) followed by
two washing steps with both, buffer I (50 mM NaH2PO4 (pH 8.0),
300 mM NaCl, 10 mM imidazole) and buffer II (50 mM
NaH2PO4 (pH 8.0), 300 mM NaCl, 20 mM imidazole), followed
by elution of the 6xHis-tagged GLEA2 protein with elution buffer
(50 mM NaH2PO4 (pH 8.0), 300 mM NaCl, 250 mM imidazole).
Enzyme-linked immunosorbent assay
For assessment of GLEA2 status, 6xHis-tagged GLEA2 protein
(1 mg/ml in 0,2% BSA/PBS) was immobilized on Ni-NTA
HisSorb Strips (Qiagen) overnight at 4uC. As a control we used
1 mg/ml BSA. Strips were four times washed with PBS containing
0,05% Tween 20 (PBST) for 30 sec. Serum samples were diluted
1?10 in 0,2% BSA/PBS and incubated overnight at 4uC followed
by four washing steps. For detection horseradish peroxidase
conjugated anti human IgG antibody (Dianova, Hamburg,
Germany) was incubated 45 min at ambient temperature. Strips
were washed 2630 s with PBST, 2630 s with PBS and dried on
paper towels. Development was performed with 3,3,5,5-Tetra-
methyl-benzidine (TMB) (MP Biomedicals, Illkirch, France)
substrate for 15–30 min. The reaction was stopped with 2 M
H2SO4 and the absorption was monitored at 450/690 nm with an
ELISA reader. ELISA assay was performed with 24 glioblastoma
sera, 30 lung carcinoma sera and 30 sera from healthy donors.
Statistical methods
We analyzed whether the changes of the GLEA2 levels between
two consecutive measurement points in our time course are
statistically significant. To this end, we applied unpaired two-tailed
Wilcoxon Mann-Whitney test on our ELISA values. Alterations
with a p-value ,0.05 were considered as statistically significant.
Results
Threshold determination and separation of glioblastoma
and control sera
Our previous study on the seroreactivity of GLEA2 was
performed by SEREX or by spot assays. Since these approaches
do not allow a quantitative analysis we studied the seroreactivity of
GLEA2 by ELISA. In detail, we expressed N-terminal 6xHis-
tagged GLEA2 in a baculovirus expression system to permit
eukaryotic posttranslational modification of GLEA2. We analyzed
the serostatus of 24 glioblastoma patients from the time prior to
surgery throughout the further development of their disease. As
control we included 30 healthy volunteers as well as 30 lung cancer
patients. Recently, abundantly expression of GLEA2 was found in
lung carcinoma of patients who underwent excessive chemother-
apy [14]. As negative control for the ELISA assay, we used Ni-
NTA strips treated with BSA only. We obtained readout values
between 0 and 0.587. We empirically determined a threshold of
0.1 to achieve the best separation between glioblastoma patients
and controls.
The difference of GLEA2 values between the controls and the
glioblastoma patients was statistically significant as shown by
unpaired two-tailed Wilcoxon Mann-Whitney test (glioblastoma
vs. normal p-value 0.017; glioblastoma vs. lung p-value 0.0021). In
contrast the difference between lung cancer patients and healthy
volunteers was statistically not significant (p-value 0.92). The Box-
Whisker-Plot in Figure 1A provides the median and interquantile
range of the ELISA data for normal sera, lung cancer sera and the
glioblastoma sera that were obtained before surgery.
In addition, we calculated the percentage of patients with
GLEA2 ELISA values above the chosen threshold. In the
following, this number is referred to as seroreactivity frequency.
We obtained an overall seroreactivity frequency of 52.4% for
glioblastoma patients. Previously we described an antibody
response against GLEA2 in 48.4% of glioblastoma patients using
SEREX and spot assays (13). The slight difference is likely due to
different techniques used in both studies.
GLEA2 seroreactivity course
To follow up on the course of the overall GLEA2 seroreactivity,
we analyzed 24 glioblastoma patients not only prior to surgery, but
also at different times after surgery. The second measurement was
immediately after surgery, the third measurement prior to
radiotherapy, the fourth measurement during radiotherapy and
the fifth measurement after radiation.
The GLEA2 read out values of the five measurements are
provided as Box-Whisker-Plot (Fig. 1B). As shown by this figure,
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the lowest overall frequency after surgery and prior to radiation.
The highest average seroreactivity was found during radiotherapy
and subsequent to radiotherapy. The only statistically significant
difference between two consecutive measurement points was
between prior to radiation and during radiation (p-value of 0.014).
For each time point we also calculated the percentage of patients
with GLEA2 ELISA values above the chosen threshold. As stated
above, we obtained an overall seroreactivity frequency of 52.4% for
the time point prior to surgery. For the time point immediately after
surgery we obtained an overall seroreactivity frequency of 65.2%
and for the time point prior to radiation a frequency of 36.8%.
During and after radiation we found more than 60% of patients
with GLEA2 ELISA values above the chosen threshold.
Increase of GLEA2 seroreactivity after radiotherapy
To follow up the GLEA2 seroreactivity of each individual
patient, we compared GLEA2 values between two consecutive
time points. For one third of the patients the GLEA2 values were
similar before and after surgery. In Figure 2A, GLEA2 values on
or near the diagonal indicate these cases. For the majority of the
remaining cases we found an increase of GLEA2 values after
surgery visualized by GLEA2 values above the diagonal in
Figure 2A. For the minority of cases we found a decrease in
GLEA2 values after surgery visualized by the values below the
diagonal. Likewise, we compared the GLEA2 values after surgery
and prior to radiation for each patient. As demonstrated in
Figure 2B we found more GLEA2 values below the diagonal than
above indicating a decrease of GLEA2 values. Comparing the
GLEA2 values before and during radiotherapy, we found the
majority of the values above the diagonal indicating a strong
increase of GLEA2 seroreactivity (Figure 2C). Comparing the
GLEA2 values during and after radiation we found similar numbers
of GLEA2 values above or below the diagonal indicating that
GLEA2 values did not obviously change after radiation (Fig. 2D).
To compute significance values for consecutive points in time, we
performed an unpaired two tailed Wilcoxon Mann-Whitney tests.
Consistent with the analysis of the overall GLEA2 seroreactivity
frequency, the differences between GLEA2 values prior to radiation
and during radiation were significant (p-value of 0.014).
Individual GLEA2 course
We attempted to group the GLEA2 ELISA values according to
their time course. We found five patients that had ELISA values
above the threshold throughout the time, and four patients that
had values below the threshold throughout the time. The
remaining 15 patients showed GLEA2 values that changed over
time. Out of seven patients that had high GLEA2 values prior to
surgery, five patients showed decreased GLEA2 values prior to
radiation. Out of these five patients, three showed again increased
GLEA2 values during and after radiation. Out of seven patients
that had low GLEA2 values prior to surgery, six had also increased
GLEA2 values during and after radiation.
GLEA2 course of seropositive and seronegative patients
We compared the median GLEA2 values between patients that
were negative for GLEA2 autoantibodies prior to surgery and
patients that were positive for GLEA2 autoantibodies prior to
surgery. GLEA2 postive patients showed a strong decline of
GLEA2 values after surgery followed by an increase of GLEA2
values to a higher level during radiation. After surgery, GLEA2
negative patients showed GLEA2 levels similar to the levels of
GLEA2 positive patients. During radiation, GLEA2 negative
patients showed an increase of GLEA2 values. This increase was
Figure 1. GLEA2 seroreactivity. (A) Comparison of GLEA2 seroreactivity between glioblastoma patients, healthy volunteers, and lung cancer
patients as control groups. The differences between the controls and the glioblastoma patients group were statistically significant. The difference
between the two control groups was not significant. (B) Comparison of GLEA2 seroreactivity between glioblastoma patients prior to surgery, after
surgery, prior to radiation, during radiation and after radiation. The differences were significant between pre-radiation and during radiation. Black
bars correspond to median values, the dazed lines to the 75% quantiles, circles represent outliers.
doi:10.1371/journal.pone.0002164.g001
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patients. Both, GLEA2 positive and GLEA2 negative patients
showed a slight decline of the GLEA2 values after radiation
(Figure 3). We also compared the median GLEA2 values between
patients that were treated by different regimens of temozolomide
and patients that were treated by radiotherapy only. We did not
found any statistically significant difference of GLEA2 values
between these patients groups.
Figure 2. Individual course of GLEA2 seroreactivity. Each mark represents the GLEA2 value of a single patient. (A) Comparison of GLEA2
seroreactivities prior and after surgery. (B) Comparison of GLEA2 seroreactivities after surgery and prior to radiation. (C) Comparison of GLEA2
seroreactivities prior and during radiation. (D) Comparison of GLEA2 seroreactivities during and after radiation. On the right of each figure, a
histogram of the quotient of GLEA2 values at the two time points is shown.
doi:10.1371/journal.pone.0002164.g002
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Recent evidence indicated modulation of the MHC class I
expression and the peptide repertoire by ionizing radiation.
Radiation of a melanoma cell line lead to increased peptide
production and antigen presentation [5]. Immunotherapy allowed
eradication of a murine colon adenocarcinoma only when
preceded by radiotherapy of the tumor tissue [5]. These results
lead us to ask how radiation influences the seroreactivity of
antigens in human tumor patients. We chose to analyze
glioblastoma patients that have a very poor prognosis despite
surgery and radiotherapy. In addition, immunotherapy for tumors
located in the CNS has generally not achieved the results reported
for some peripherally located tumors. The relative paucity of
glioma-associated antigens that can be targeted by the immune
system may partially account for this situation [8–13].
Our results provide first in vivo evidence that radiation may
increase the frequency of the autologous antibody response
against human tumor antigens. Without further experimental
evidence, we can, however, not rule out that the increased
GLEA2 values are due to other factors but radiation. We were
not able to compare the GLEA2 values between patients with
and without radiation. The majority of glioblastoma patients
undergoes radiotherapy after surgery even in clinical trials like
the phase III NOA-8 trial and patients who are not treated by
radiation generally showed a Karnofsky Performance Score
lower 60.
However several observations lead us to conclude that the
increase in GLEA2 autoantibodies is likely due to radiation. In
general we found an increase of GLEA2 values during radiation
and a subsequent decrease of GLEA2 values after radiation. It
appears unlikely that these GLEA2 values are due to tumor
growth pattern: The median residual tumor volume after gross-
total removal is reduced to 12% as shown by quantitative
radiological analysis [15]. Provided the mean tumor doubling time
of glioblastoma is 24 days [16], the GLEA2 measurements prior
to radiation were performed after 0.13 doubling times. The
measurements during and after radiation were performed after 2.0
and 5.5 doubling times. The resulting increase of tumor volume
does not readily explain the strong increase of GLEA2
autoantibodies during radiation and the slight decrease after
radiation.
It is also conceivable that radiation can elicit an antibody
response against novel antigens that are not immunogenic in
glioma patients without radiation. Our finding is in keeping with
this idea since GLEA2 was immunogenic in some patients only
during or after but not prior to radiation. In the future, radiation
may significantly improve the results of immunotherapy for
tumors located in the CNS. Modulating the tumor immunor-
esponse can contribute to overcome the current shortcomings of
immunotherapy.
Our results provide also evidence that the analysis of antigen
seroreactivity may be useful for monitoring tumor development
under treatment. The immune system may be ideally suited to
identify even subtle changes in tumor development that cannot be
picked up by other approaches. Future developments can combine
the power of imaging technology and the sensitivity of approaches
that utilize the immune system for tumor detection. Detection and
monitoring of human tumors by seroreactivity of antigens is,
however, still in its infancy. Out of the over 2000 antigens known
to be immunogenic in human tumor patients, only very few have
been analyzed for the course of their seroreactivity during tumor
progression under treatment [17]. There are no studies that follow
the antigen reactivity during the progress of human brain tumors.
Surpassing the scope of our study, an optimized monitoring of
brain tumor development under treatment would require an
extended number of immunogenic antigens that yet need to be
identified.
Our study does not focus on the question why radiation results
in increased GLEA2 seroreactivity. One obvious explanation is the
release of GLEA2 as the result of cell destruction due to radiation.
The increased GLEA2 seroreactivity found in glioblastoma
patients at the time of surgery may also be caused by necrosis
that is typically associated with human glioblastoma. Alternatively,
GLEA2 may also be presented via MHC class I on the surface of
glioblastoma cells [5]. However, MHC class I antigen presentation
is remarkably inefficient. This may be overcome by radiation that
both enhance degradation of cellular proteins and MHC class I
expression.
Independent of the molecular mechanisms, the study indicates
that radiation increases the antibody response against GLEA2 in
glioma patients. Although obtaining blood at defined time points
after surgery may be difficult for a larger number of
glioblastoma patients, our study provides strong evidence that
it is worthwhile (a) to identify further antigens that are
immunogenic in glioblastoma patients and (b) to follow the
course of their seroreactivity during glioma development under
treatment. Only the analysis of seroreactivity over longer periods
can fully reveal the value of immunogenic antigens for tumor
monitoring.
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Figure 3. Main course of GLEA2 seroreactivity. Line plot of
median GLEA2 values on the five measurement times. The median
values of all 24 glioblastoma patients (red line) were compared to two
patient subgroups. Patients that were GLEA2 positive prior to surgery
were indicated by blue line. Patients that were GLEA2 negative prior to
surgery were indicated by black line.
doi:10.1371/journal.pone.0002164.g003
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